Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Mid Cap Value Fund”. A copy of the letter can be downloaded here. The Fund seeks to invest in undervalued companies with solid financial health and compelling business economics. US equities continued to advance in the fourth quarter of 2025, despite volatility. At the start of the quarter, a government shutdown unsettled investors and delayed key economic data, raising questions about the Federal Reserve’s easing timeline. However, as the quarter progressed, risk appetite increased, and clarity around monetary policy improved, leading the Fed to implement rate cuts and end quantitative tightening. This suggests a continued easing of financial conditions into 2026. While AI remained a key focus, markets diversified in November, with value and non-AI stocks leading. This could indicate a shift in market leadership moving forward. Mid-cap stocks lagged large caps in Q4, particularly on the growth side, as the Russell Midcap® Growth Index declined 3.7% while mid-cap value posted a modest gain and outperformed the growth index for the quarter and full year. In the quarter, the fund’s Investor Class fund ARTQX returned 1.53%, Advisor Class fund APDQX posted a return of 1.54%, and Institutional Class fund APHQX returned 1.63%, compared to a 1.42% return for the Russell Midcap Value Index. Please review the Fund’s top five holdings to gain insights into their key selections for 2025.
In its fourth-quarter 2025 investor letter, Artisan Mid Cap Value Fund highlighted stocks like Revvity, Inc. (NYSE:RVTY). Revvity, Inc. (NYSE:RVTY) is a life sciences and diagnostics company that provides health sciences solutions, technologies, and services. On March 31, 2026, Revvity, Inc. (NYSE:RVTY) stock closed at $87.61 per share. One-month return of Revvity, Inc. (NYSE:RVTY) was -11.05%, and its shares lost 17.91% over the past 52 weeks. Revvity, Inc. (NYSE:RVTY) has a market capitalization of $9.8 billion.
Artisan Mid Cap Value Fund stated the following regarding Revvity, Inc. (NYSE:RVTY) in its fourth quarter 2025 investor letter:
“Another notable purchase was Revvity, Inc. (NYSE:RVTY), a life sciences and diagnostics company that was a 2023 spinoff of PerkinElmer. That move created a streamlined company, with high recurring revenue, increased margins andbetter growth prospects. Our investment thesis centers on Revvity’s life sciences segment, particularly BioLegend reagents and the Signals software platform, which benefits from high barriers to entry, strong customer stickiness and long-term tailwinds from rising biopharma R&D, looming patent cliffs and the need for greater research efficiency. BioLegend is viewed as a best-in-class asset with structural cost, quality and logistics advantages that drive share gains and attractive margins in consumable, recurring end markets. Meanwhile, Signals software offers sticky, mission-critical informatics tools with high retention and expansion potential, trading at valuations that appear disconnected from recent takeout multiples in the sector. The company’s diagnostics segment provides stable cash flow and incremental growth through menu and geographic expansion, particularly in newborn screening and autoimmune testing, partially offset by near-term pressure in China. With solid free cash flow generation, manageable leverage and active share repurchases, the shares trade at a meaningful discount to peers and implied sum-of-the-parts value, offering an attractive risk-reward as growth and margins normalize, in our view.”
Revvity, Inc. (NYSE:RVTY) is not on our list of 40 Most Popular Stocks Among Hedge Funds. According to our database, 35 hedge fund portfolios held Revvity, Inc. (NYSE:RVTY) at the end of the fourth quarter, up from 22 in the previous quarter. While we acknowledge the risk and potential of Revvity, Inc. (NYSE:RVTY) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Revvity, Inc. (NYSE:RVTY) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Revvity, Inc. (NYSE:RVTY) and shared Emerald Growth Equity Strategy’s views on the company. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
